Based on data from studies in other cancers, certain biomarkers could be potentially associated with platinum resistance in EPNEC and SCLC such as ERCC1 (Excision repair cross-complementation group 1), Lin28a, Bcl-2 (B-cell lymphoma 2) and Ki-67. This evidence concerns the gene MKI67 and small cell lung carcinoma.